Ranibizumab as Adjuvant Therapy for the Treatment of Choroidal Melanoma (Cohort 2)

PHASE2CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

July 31, 2010

Primary Completion Date

July 31, 2012

Study Completion Date

August 31, 2012

Conditions
Choroidal Melanoma
Interventions
DRUG

Ranibizumab 2 mg

intravitreal injections of ranibizumab once a month, times 3.

DRUG

0.5 mg Ranibizumab

6 intravitreal injections of 0.5 mg Ranibizumab every 2 weeks x 3 months.

Trial Locations (1)

06518

New England Retina Associates, Hamden

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

New England Retina Associates

OTHER